OraSure Technologies (NASDAQ:OSUR) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.
A number of other research firms also recently issued reports on OSUR. Zacks Investment Research downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, November 4th. Jefferies Group restated a “buy” rating and set a $23.00 target price on shares of OraSure Technologies in a research report on Friday, October 20th. Finally, ValuEngine downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. OraSure Technologies presently has an average rating of “Buy” and an average target price of $19.65.
OraSure Technologies (OSUR) opened at $21.71 on Friday. OraSure Technologies has a 52-week low of $8.39 and a 52-week high of $23.01. The stock has a market cap of $1,304.55, a PE ratio of 41.75, a price-to-earnings-growth ratio of 4.82 and a beta of 1.27.
In other news, Director Mara G. Aspinall purchased 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 7th. The shares were acquired at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $71,150. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.40% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. Profund Advisors LLC raised its position in shares of OraSure Technologies by 2.8% in the 2nd quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 293 shares during the period. Victory Capital Management Inc. raised its holdings in OraSure Technologies by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock worth $157,000 after buying an additional 1,360 shares during the period. The Manufacturers Life Insurance Company raised its holdings in OraSure Technologies by 3.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,672 shares of the medical instruments supplier’s stock worth $772,000 after buying an additional 1,573 shares during the period. Principal Financial Group Inc. raised its holdings in OraSure Technologies by 0.7% during the 3rd quarter. Principal Financial Group Inc. now owns 482,574 shares of the medical instruments supplier’s stock worth $10,858,000 after buying an additional 3,531 shares during the period. Finally, Teachers Retirement System of The State of Kentucky raised its holdings in OraSure Technologies by 24.4% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 19,400 shares of the medical instruments supplier’s stock worth $335,000 after buying an additional 3,800 shares during the period. Institutional investors and hedge funds own 94.43% of the company’s stock.
WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/20/orasure-technologies-osur-upgraded-by-bidaskclub-to-strong-buy.html.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.